Thorne Healthtech (NASDAQ:THRN) Stock Rating Lowered by Zacks Investment Research

Thorne Healthtech (NASDAQ:THRN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks.com reports.

According to Zacks, “Thorne HealthTech is involved in developing solutions for a personalized approach to health and wellbeing. It provides personalized solutions to consumers, health professionals and corporations. The company’s integrated brand includes Thorne and Onegevity. Thorne HealthTech is based in NEW YORK. “

Several other equities research analysts also recently commented on the company. Bank of America started coverage on Thorne Healthtech in a report on Monday, October 18th. They set a “buy” rating and a $11.00 target price on the stock. Cowen began coverage on Thorne Healthtech in a report on Monday, October 18th. They issued an “outperform” rating and a $11.00 price target for the company. Evercore ISI began coverage on Thorne Healthtech in a research report on Monday, October 18th. They set an “outperform” rating and a $13.00 price objective for the company. Finally, Royal Bank of Canada started coverage on Thorne Healthtech in a research report on Monday, October 18th. They set an “outperform” rating and a $11.00 price objective for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $10.60.

NASDAQ:THRN opened at $6.41 on Thursday. The business has a fifty day simple moving average of $7.31. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.67 and a quick ratio of 1.86. Thorne Healthtech has a 1 year low of $5.20 and a 1 year high of $10.13.

Thorne Healthtech (NASDAQ:THRN) last posted its quarterly earnings data on Wednesday, November 10th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. The company had revenue of $48.01 million for the quarter. As a group, sell-side analysts anticipate that Thorne Healthtech will post 0.2 EPS for the current year.

A number of large investors have recently made changes to their positions in THRN. Samson Rock Capital LLP acquired a new stake in Thorne Healthtech during the 3rd quarter valued at $303,000. Emerald Advisers LLC acquired a new stake in shares of Thorne Healthtech in the 3rd quarter valued at about $3,822,000. Emerald Mutual Fund Advisers Trust acquired a new stake in shares of Thorne Healthtech in the 3rd quarter valued at about $3,963,000. Monashee Investment Management LLC acquired a new stake in shares of Thorne Healthtech in the third quarter valued at about $3,082,000. Finally, Teacher Retirement System of Texas bought a new position in Thorne Healthtech during the third quarter worth about $1,946,000. Hedge funds and other institutional investors own 11.81% of the company’s stock.

About Thorne Healthtech

Thorne HealthTech is involved in developing solutions for a personalized approach to health and wellbeing. It provides personalized solutions to consumers, health professionals and corporations. The company’s integrated brand includes Thorne and Onegevity. Thorne HealthTech is based in NEW YORK.

Further Reading: What is Cost of Capital?

Get a free copy of the Zacks research report on Thorne Healthtech (THRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Thorne Healthtech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thorne Healthtech and related companies with MarketBeat.com's FREE daily email newsletter.